Patent ID: 11866789
Assignee: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC A  C  G

Claim 16:
17. A method for selecting a chemotherapy regimen for a patient to treat cholangiocarcinoma, the method comprising the steps of:
collecting a genetic sample from a patient's cholangiocarcinoma tumor;
analyzing the genetic sample for a RBPMS-NRG1 fusion transcribed from an interchromosomal DNA translocation in chromosome 8 band p12;
identifying a RBPMS-NRG1 fusion in the genetic sample, wherein the NRG1 portion of the fusion comprises a EGF-like domain on the NRG1 portion receptor of the fusion, wherein the RBPMS-NRG1 fusion includes exons 1-5 of RBPMS and exons 1 and 2 of NRG1;
selecting a chemotherapy regimen for the patient, having the RBPMS-NRG1 fusion, comprising at least one treatment with an EGFR inhibitor that is targeted for the EGF-like domain of the NRG1 portion of the RBPMS-NRG1 fusion event; and
treating the patient with a therapeutic agent comprising the EGFR inhibitor that is targeted for the EGF-like domain of the NRG1 portion of the RBPMS-NRG1 fusion event.